| Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer’s Disease EN Minakawa, K Wada, Y Nagai International journal of molecular sciences 20 (4), 803, 2019 | 104 | 2019 |
| Transgenic monkey model of the polyglutamine diseases recapitulating progressive neurological symptoms I Tomioka, H Ishibashi, EN Minakawa, HH Motohashi, O Takayama, ... eNeuro 4 (2), ENEURO. 0250-16.2017, 2017 | 72 | 2017 |
| Chronic sleep fragmentation exacerbates amyloid β deposition in Alzheimer’s disease model mice EN Minakawa, K Miyazaki, K Maruo, H Yagihara, H Fujita, K Wada, ... Neuroscience letters 653, 362-369, 2017 | 66 | 2017 |
| Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly LM Sharkey, N Safren, AS Pithadia, JE Gerson, M Dulchavsky, S Fischer, ... Proceedings of the National Academy of Sciences 115 (44), E10495-E10504, 2018 | 63 | 2018 |
| F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing G Atkin, J Hunt, E Minakawa, L Sharkey, N Tipper, W Tennant, ... Journal of Biological Chemistry 289 (10), 7038-7048, 2014 | 41 | 2014 |
| Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases EN Minakawa, Y Nagai Frontiers in Neuroscience 15, 75, 2021 | 40 | 2021 |
| Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation EN Minakawa, HA Popiel, M Tada, T Takahashi, H Yamane, Y Saitoh, ... Brain 143 (6), 1811-1825, 2020 | 33 | 2020 |
| Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3 L Zeng, B Wang, SA Merillat, EN Minakawa, MD Perkins, B Ramani, ... Neurobiology of disease 82, 281-288, 2015 | 28 | 2015 |
| Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease Y Yamamoto, K Kojima, D Taura, M Sone, K Washida, N Egawa, T Kondo, ... Molecular Brain 13 (1), 1-12, 2020 | 25 | 2020 |
| E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease R Sakai, M Suzuki, M Ueyama, T Takeuchi, EN Minakawa, H Hayakawa, ... PloS one 14 (6), e0218261, 2019 | 16 | 2019 |
| Drug Development for Neurodegenerative Diseases Y Nagai, EN Minakawa Neurodegenerative Disorders as Systemic Diseases, 183-216, 2015 | 10 | 2015 |
| A case of follicular lymphoma associated with paraneoplastic cerebellar degeneration Y Shimazu, EN Minakawa, M Nishikori, M Ihara, Y Hashi, H Matsuyama, ... Internal Medicine 51 (11), 1387-1392, 2012 | 10 | 2012 |
| Chicken DT40 cell line lacking DJ-1, the gene responsible for familial Parkinson's disease, displays mitochondrial dysfunction EN Minakawa, H Yamakado, A Tanaka, K Uemura, S Takeda, ... Neuroscience research 77 (4), 228-233, 2013 | 6 | 2013 |
| Generation of disease-specific induced pluripotent stem cells from sporadic Parkinson's disease patients T Kondo, H Inoue, E Minakawa, Y Koshiba, K Washida, N Egawa, ... Neuroscience Research, e191, 2011 | 3 | 2011 |
| Transgenic monkey model of the polyglutamine diseases recapitulating progressive neurological symptoms and polyglutamine protein inclusions Y Nagai, I Tomioka, H Ishibashi, EN Minakawa, HH Motohashi, ... Journal of the Neurological Sciences 381, 55, 2017 | 1 | 2017 |
| “Impaired sleep quality” and dementia E MINAKAWA, K WADA, Y NAGAI Dementia Japan 34 (2), 139-145, 2020 | | 2020 |
| Pharmaceutical composition Y Nagai, HA Popiel, E Minakawa US Patent App. 16/312,208, 2019 | | 2019 |
| Sleep Abnormality as a Potential Target of Disease-Modifying Therapy for Neurodegenerative Diseases EN Minakawa Nihon yakurigaku zasshi. Folia pharmacologica Japonica 154 (6), 306-309, 2019 | | 2019 |
| Molecular Modulators of Ubqln2 Aggregation: Implications in Aging and Neurodegeneration L Sharkey, M Ivanova, N Safren, A Pithadia, J Gerson, M Dulchavsky, ... PROTEIN SCIENCE 27, 154-155, 2018 | | 2018 |
| Bidirectional Relationship between Sleep Debt and Neurological Diseases Implications from Animal Studies E MINAKAWA ストレス科学 33 (1), 65-71, 2018 | | 2018 |
